Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 4/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | IL1B | P01584 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30896328 | 0.87 | CRBN (0.74) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL1962200 | 0.87 | CRBN (0.74) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL4674905 | 0.87 | CRBN (0.74) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL476905 | 0.87 | CRBN (0.74) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL8259914 | 0.82 | CRBN (0.57) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL25565709 | 0.81 | DDB1 (0.51) | DDB1CRBN | |
| SCHEMBL7859338 | 0.76 | DDB1 (0.47) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL6179617 | 0.76 | DDB1 (0.74) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL2049089 | 0.76 | DDB1 (0.74) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL2049091 | 0.76 | DDB1 (0.74) | DDB1CRBNTNFIL1BTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9857359-B2 | Methods for determining drug efficacy using cereblon-associated proteins | CELGENE CORPORATION (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160313300-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORP (US) | 2016-10-27 | — | — | US | disclosed |
| US-20140162282-A1 | METHODS FOR DETERMINING DRUG EFFICACY USING CEREBLON-ASSOCIATED PROTEINS | CELGENE CORPORATION (US) | 2014-06-12 | — | — | US | disclosed |
| US-20090222080-A1 | MEDICAL STENT PROVIDED WITH INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | PICARUS NV SA (LU) | 2009-09-03 | — | — | US | disclosed |
| US-7459466-B2 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNFα levels | CELGENE CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160313300-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | BCL9, BCL9L, IKZF1 | DDB1 52/4885CRBN 5/4885TNF 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.